Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.
Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...
Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee. The company has adjusted certain Board committee memberships alongside his appointment. The changes bring additional financial and life sciences experience into Moderna’s governance structure. Moderna, traded on NasdaqGS:MRNA, is drawing attention for a fresh governance update rather than product news. The stock closed at $59.66, with returns up 93.3% year to date and up 82.3% over the past year, set...
The biotech has been on a tear lately.
A fresh era of earnings growth may be on the horizon.
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.
On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company’s late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a...
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.
Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.
The Morning Bull - US Market Morning Update Monday, Jul, 13 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in...
The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May.
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.
The Iran war and a tug-of-war between AI stocks and other parts of the market have left the S&P 500 stuck in a range. On Friday, the S&P 500’s healthcare sector was the only major sector trading down more than 0.1%: It was down 0.7%. Moderna was the S&P’s biggest laggard, while UnitedHealth was the big drag on the Dow.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to procure up to 24 million doses of the company's vaccine for Respiratory Syncytial Virus (RSV).
Moderna has delivered a sharp 148.1% gain year to date, yet its low value score and rich market multiples suggest the stock is far from a clear bargain. Year to date, Moderna is up 148.1%, which puts recent enthusiasm firmly ahead of its longer term share price record. Excitement around Moderna's expanded mRNA pipeline beyond vaccines can support growth expectations, while concerns about ongoing losses and the time it may take to turn that pipeline into steady cash flow remain a key risk for...
Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.
Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said […]
On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
